In one aspect, a method includes but is not limited to obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In one aspect, a system includes but is not limited to circuitry for obtaining a priori implant information and circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants. In addition to the foregoing, other system aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a method includes but is not limited to obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In one aspect, a system includes but is not limited to circuitry for obtaining a flow-change-indicative measurement and circuitry for signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement. In addition to the foregoing, other system aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a method includes but is not limited to obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In one aspect, a system includes but is not limited to circuitry for obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and circuitry for accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens. In addition to the foregoing, other system aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a system includes but is not limited to one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature. In addition to the foregoing, other system aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer. In addition to the foregoing, various other method and/or system aspects are set forth and described in the teachings such as text (e.g., claims and/or detailed description) and/or drawings of the present disclosure.
The foregoing is a summary and thus contains, by necessity, simplifications, generalizations and omissions of detail; consequently, those skilled in the art will appreciate that the summary is illustrative only and is NOT intended to be in any way limiting. Other aspects, features, and advantages of the devices and/or processes and/or other subject matter described herein will become apparent in the teachings set forth herein.
Those having skill in the art will recognize that the state of the art has progressed to the point where there is little distinction left between hardware and software implementations of aspects of systems; the use of hardware or software is generally (but not always, in that in certain contexts the choice between hardware and software can become significant) a design choice representing cost vs. efficiency tradeoffs. Those having skill in the art will appreciate that there are various vehicles by which processes and/or systems and/or other technologies described herein can be effected (e.g., hardware, software, and/or firmware), and that the preferred vehicle will vary with the context in which the processes and/or systems and/or other technologies are deployed. For example, if an implementer determines that speed and accuracy are paramount, the implementer may opt for a mainly hardware and/or firmware vehicle; alternatively, if flexibility is paramount, the implementer may opt for a mainly software implementation; or, yet again alternatively, the implementer may opt for some combination of hardware, software, and/or firmware. Hence, there are several possible vehicles by which the processes and/or devices and/or other technologies described herein may be effected, none of which is inherently superior to the other in that any vehicle to be utilized is a choice dependent upon the context in which the vehicle will be deployed and the specific concerns (e.g., speed, flexibility, or predictability) of the implementer, any of which may vary. Those skilled in the art will recognize that optical aspects of implementations will typically employ optically-oriented hardware, software, and or firmware.
In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. The use of the same symbols in different drawings typically indicates similar or identical items. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented here.
With reference now to
In some variants, one or more upper modules 150 in vicinity 135 may (optionally) send data to and/or receive data from one or more instances of intravascular or other sensors 110 in vicinity 105. Upper module 150 may likewise comprise one or more instances of modules 113, 114 of dispensing logic 115; dispensers 117, 118, 119; modules 121, 122 of evaluation logic 120; transmitters 147, receivers 148, or other modules 141, 142, 143 of interface logic 140; or modules 151, 152 of response logic 155. Interface logic may (optionally) handle data to output device 126 and/or from input device 128 as well interacting with one or more lower modules 190. Lower module 190 may include one or more instances of microfluidic or other pumps 176, ports 177, dispensers 178, sensors 179, or semi-permeable membranes 181 or other such modules 182 or vessels 183 of extraction devices 180.
With reference now to
In some variants, one or more intravascular or other modules 250 in vicinity 225 may (optionally) include one or more instances of sensors 210; modules 223 or other dispensing logic 220; dispensers 228, 229; or transmitters 247, receivers 248, or other interface logic 240. (Some such modules 250 may be operable for penetrating a vascular structure with ultrasonic or other energy, for example, or may comprise an implanted cannula or other transvascular structure.) Module 223 may, as shown, comprise one or more instances of port controls 221, regimens 222 or other programmatic dispensing information (optionally embodied in software or other instruction sequences, for example), or requests or other messages 224.
Alternatively or additionally, system 200 may comprise one or more intravascular or other sensors 290 that may (optionally) be configured to communicate (in one or both directions) with module 250, such as by a signal-bearing conduit or radio-frequency signal. (Some such sensors 290 may be operable for monitoring one or more physical phenomena within vascular structures, for example, from within or in a vicinity of the structures.) Systems 200 may likewise be configured to include or otherwise interact with one or more instances of external modules 280 operable, for example, for obtaining and providing data 285 as described herein. In some variants, for example, the one or more sensors 290 are only operable for communicating sensed analog or digital values to module 250. In others, one or more of the sensor(s) 290 are able to receive updates or other information from one or more external modules 280 or other transmitters 247 as described herein.
With reference now to
Flow 300 further comprises operation 380—signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants (e.g. interface logic 240 invoking one or more modules 223 of dispensing logic 220 operable for activating one or more dispensers 228 containing one or more thrombolytic agents or other locally-administered therapeutic materials selectively when apparently needed in a vicinity 275 of lumen 295). This can occur, for example, in a context in which the a priori implant information indicates a drug-eluting stent or other potentially thrombogenic implant at outflow 299.
With reference now to
In some variants, module 460 may (optionally) include one or more instances of modules 413, 414 of dispensing logic 415; dispensers 417, 418, 419; modules 421, 422 of evaluation logic 420; interface logic 440; modules 451 or other response logic 455; or intravascular or other sensors 450. (Some such sensors 450 may be operable for monitoring radiant or other physical phenomena within a lumen 495, for example, from within or in a detection vicinity 405 of lumen 495.) Interface logic 440 may, as shown, comprise one or more instances of transmitters 447, receivers 448, or other modules 442 operable for communicating (in one or both directions) with one or more sensors 410 in (upstream) vicinity 405 of lumen 495.
With reference now to
Flow 500 further comprises operation 590—signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement (e.g. one or more modules 413, 414 of dispensing logic 415 causing one or more dispensers 417, 418 to administer an antiplatelet-drug-containing or other therapeutic agent in response to the one or more modules 421, 422 of evaluation logic 420). This can occur, for example, in a context in which module 414 specifically selects such a therapeutic material by selecting the dispenser 418 containing the material in lieu of another dispenser. Alternatively or additionally, one or more modules 442 may be configured to signal the decision in some other way, such as by a speaker or other transmitter 447 conveying medication instructions to the (implanted) subject, or otherwise by sending such a message to a party who is able to implement the decision.
With reference now to
Next downstream as shown, module 690 comprises one or more modules 631, 632 of response logic 635; (transvascular or other) extraction modules 645; sensors 681; dispensers 682; or clamps 655. As shown, extraction module 645 comprises one or more ports 641 to be formed through vessel wall 646, operable for extracting a portion 644 of lytic-material-infused blood 642, for example, into one or more absorbent elements 647 and/or to other disposal vessels at a lower-than-ambient pressure. As shown, one or more clamps 655 are configured to limit outflow 699 from module 690 by expanding one or more actuators 657, thereby levering lumen 695 to occlude it temporarily as shown. Alternatively or additionally, vicinity 685 of lumen 695 may include one or more conduits 667 operable for selectively removing a portion of outflow 699 by redirecting it to one or more artificial disposal vessels 670 as shown.
With reference now to
Flow 700 further comprises operation 770—accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens (e.g. port 641 or conduit 667 opening shortly after a dispensation of fibrinolytic material in upstream vicinity). This can occur, for example, in embodiments in which such ports or conduits are configured to allow higher-than-nominal concentrations of the lytic material to drain out of the vascular system, optionally by a timely exposure to an absorbent element 647 or other disposal vessel 670. Alternatively or additionally, such extraction may (optionally) be performed actively, such as by microfluidic or other pumps as described herein.
With reference now to
In some variants, one or more intravascular or other modules 850 may (optionally) include one or more instances of receivers 825, transmitters 826, or other interface logic 820 such as for communicating (in one or both directions) with one or more sensors 810 operable for monitoring upstream portion 846. Module 850 may likewise include one or more instances pumps 827 or other hardware controlled by dispensing logic 830 for selectively releasing one or more (biological, radiotherapy, or other) agents 841 or other therapeutic structures 842 into upstream portion 846. Such module(s) 850 may also be configured, in some contexts, by including one or more software or other modules 833 of dispensing logic 830 comprising one or more instances of port controls 831, (dispensing or other therapeutic) regimens 832, or messages 834 as described below.
As shown, system 800 may comprise one or more modules 850 upstream operable for communicating (in one or both directions) with one or more intravascular or other modules 890 downstream, optionally in an integral and/or implanted structure as shown. Alternatively or additionally, module 890 may include one or more instances of capture agents 867, 868 or other therapeutic agents 869; receivers 878; sensors 879; capture logic 880 operable for controlling one or more actuators 881, such as for optically or otherwise controlling the capture agent(s); pumps 887; or disposals 888, 889. As shown, for example, disposal 889 may include one or more ports 882 operable for accelerating a decrease in a local concentration of the agent(s) 841 or other therapeutic structure(s) 842 along portion 876 (downstream from dispensation 897, as shown) by allowing the structure(s) to pass into one or more conduits 886 traversing one or more vessel walls 883, 884. One or more vessels 885 configured to receive the structure(s) may include, in some embodiments, an esophagus or other natural vessels, implanted vessels, or ex situ vessels. Concerning the opening of port 641 or other timing of capture logic 880 or similar responsive circuitry described herein, a delay time between a capture site and an upstream site can be readily estimated with fair vasculature. A human blood cell typically travels about ⅓ of a millimeter per second in capillaries, for example. In some contexts, an accurate model may best be developed by measuring a specific interpositional delay empirically using, for example, a fluorescent material or other detectable measurement technique. Such a delay can readily be implemented in a digital or other timing feature of modules as described herein, for example, initiating a later operation at a programmed interval following a triggering event as described herein. In situations where a more reliable model is needed, a pulse-dependent, local-pressure-dependent, or other adaptive model may be appropriate, and well within the capabilities of skilled practitioners without undue experimentation in light of teachings herein.
With reference now to
An embodiment provides a system 900 comprising dispensing logic 915 or interface logic 940 operable for signaling a decision whether to initiate implant-site-targeting treatment and one or more dispensers 916 responsive to the decision. Each dispenser 916 may (optionally) include a thrombolytic agent and/or other therapeutic materials as described herein, suitable for targeting a vicinity of valve 910. The above-described “signaling” circuitry may comprise one or more of optical sensors 975, auditory sensors, flow-force-responsive elements 978, or other components suitable for providing thrombus-indicative measurements or other data suitable for informing the decision in light of teachings herein.
An embodiment provides a system 900 comprising interface logic 940 operable for signaling a decision (a) whether to initiate implant-site-targeting treatment or (b) whether to administer one or more clot-reducing agents. Alternatively or additionally, system 900 comprising may similarly provide dispensing logic using such signaling, for example, for guiding one or more dispensers 916 accordingly. Each dispenser 916 may (optionally) contain a thrombolytic agent and/or other therapeutic materials as described herein, suitable for targeting a vicinity of valve 910. The above-described “signaling” circuitry may comprise one or more of optical sensors 975, auditory sensors, flow-force-responsive elements 978, or other components suitable for providing thrombus-indicative measurements or other data suitable for informing the decision in light of teachings herein.
With reference now to
With reference now to
With reference now to
With reference now to
Operation 1344 describes obtaining the a priori implant information from one or more implantable devices (e.g. external module 280 receiving specifications or other data 285 about module 250 from a wireless or other transmitter 247 thereof). This can occur, for example, in a context in which external module 280 notifies locally-available caregivers of the existence of module 250 and/or of dispensations or dosages from it. Such information may be used to expedite care or avoid redundant dispensations, for example. Operation 1346 describes obtaining the a priori implant information from one or more objects borne by a subject. Operation 1347 describes obtaining the a priori implant information ex situ.
Operation 1382 describes obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants. Operation 1383 describes generating the decision whether to initiate the implant-site-targeting treatment partly in response to an implant type. Operation 1385 describes invoking circuitry for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants. Operation 1388 describes generating the decision whether to initiate the implant-site-targeting treatment partly in response to detecting one or more emboli in a blood flow. Any of these operations may be omitted or performed before or during one or more instances or variants of operation 340 as described above, for example.
With reference now to
Operation 1481 describes generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in a chemical composition e.g. module 223 of dispensing logic 220 causing transmitter 247 to transmit a message 224 indicating one or more treatment materials (in respective dispensers 228, 229) and/or a dispensation site local to section 270 as a programmatic response to an apparently severe hypoxic condition or other circumstance detected via one or more sensors 210, 290 operable for detecting chemical concentrations). This can occur, for example, in a context in which a caregiver can validate and/or administer the dispensation of such a treatment material via an intravenous catheter. Alternatively or additionally, the decision to administer an already-implanted material may be performed according to a programmatic crisis-response regimen 222 specified in advance by a caregiver in response to an abnormally high platelet concentration detected locally, for example, by sensor 210.
Operation 1484 describes signaling a decision whether to dispense one or more therapeutic materials from an implant. Operation 1485 describes signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant. Operation 1487 describes generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in vascular flow. Operation 1489 obtaining one or more ischemia indicators of the one or more other clot-indicative determinants.
Operation 1442 describes obtaining an update for the a priori implant information. Operation 1446 describes obtaining timing information in the a priori implant information. Operation 1448 describes obtaining an implant type of the a priori implant information. Any of these operations may be omitted or performed before, after, or interleaved with one or more instances or variants of operation 380 as described above, for example.
With reference now to
As
With reference now to
Operation 1612 describes causing at least a statin to be dispensed as the lytic material (e.g. dispensing logic 610 invoking module 611 or other circuitry for actuating statin dispenser 618 or other lytic-material-containing dispenser 619 according to one or more dosage profiles in memory 621). This can occur, for example, in embodiments in which one or more instances of modules 630 are positioned (locally) upstream from a lung or other organ 660 and in which at least a portion 661 of organ 660 has been perfused with an abnormally high concentration of lytic material (relative to a time-averaged systemic normal range, for example). Alternatively or additionally, in some variants, module 690 may be configured in a context in which one or more hemorrhage-risk determinants have been established in relation to one or more other organs in a downstream vicinity 685 of lumen 695 relative to outflow 699.
Operation 1613 describes obtaining a concentration-indicative scalar of the one or more indications of the lytic material (e.g. optical or other sensors detecting a gradational concentration measurement or other concentration-indicative value). This can occur, for example, in a context in which the lytic material includes a fluorescent or other readily detected marker material.
Operation 1617 describes dispensing the lytic material into an upstream portion of the one or more body lumens (e.g. an actuator urging tissue plasminogen activator or other lytic materials locally into a carotid or pulmonary artery responsive to an indication signifying sudden, substantial, apparent decrease of blood flow through that vessel). This can occur, for example, in a context in which one or more clots have blocked a majority of flow, in which one or more complementary or systemic determinants indicate an absence of substantial hemorrhaging, and in which a care provider has specified a preset, programmatic regimen by which such material(s) will be administered in these contingencies. Such complementary determinants may include a dangerously high local blood pressure or flow in complementary arteries, for example, of the pulmonary vasculature. Such systemic determinants may include substantial increases in (resting) heart rate or substantial decreases in blood pressure over a course of minutes or hours.
Operation 1671 describes causing the portion of the lytic material to be drawn into an artificial vessel (e.g. actuator 881 allowing one or more ports 882 to draw at least some of outflow 899 into one or more vessels 883 from lumen 895). This can occur, for example, in a context in which a dispenser has been dispensing a therapeutic material (agent 841, e.g.) containing one or more carcinogens or other ingredients having potentially undesirable side effects in outflow 899. Alternatively or additionally, pump 887 may be used for accelerating a decrease of the local concentration of such materials in a vicinity of portion 876.
Operation 1678 describes reversing a flow direction of at least some of the lytic material (e.g. a pump reversing a material flow direction at least through a conduit). This can occur, for example, in a context in which a flow is apparently restored, such as may be manifested in a return to a normal local pressure in a formerly-blocked vessel or in a complementary vessel.
With reference now to
Operation 1711 describes permitting the lytic material to perfuse one or more organs in the vicinity of the one or more body lumens (e.g. dispensing logic 610 invoking one or more dispensers 619 to inject a lytic compound or other lytic material into a renal artery or otherwise to perfuse organ 660). This can occur, for example, in an embodiment in which dispensing logic 610 can invoke other logic modules and in which system 600 implements one or more devices like those disclosed in U.S. Pat. No. 6,592,567 (“Kidney perfusion catheter”) or U.S. Pat. No. 6,514,226 (“Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney”). Alternatively or additionally, such a perfusion may reasonably be inferred at some time after a sufficiently large systemic administration of the lytic material. In some contexts this may be desirable, for example, even for a cancer patient for whom a lytic treatment in outflow 699 presents a danger. In a case in which a majority of blood flowing through module 690 is removed from a patient's vasculature into one or more conduits 667, for example, a transfusion or other blood replacement at module 690 may be provided to supplement outflow 699 (optionally with a concomitant decrease in the local concentration of the lytic material).
Operation 1714 describes signaling at least one of the one or more indications of the lytic material via a wireless signal. Operation 1716 describes detecting a marker material indicative of the lytic material in the vicinity of the one or more body lumens. Operation 1718 describes causing the lytic material to be urged into the one or more body lumens. Operation 1719 describes accelerating a dispensation of the lytic material transluminally into the one or more body lumens as a programmed response to one or more pathology-indicative signals.
Operation 1775 describes causing the lytic material to be exposed to a lytic-material-absorbent element (e.g. an actuator opening a port so that lytic-material-containing fluid comes into contact with one or more foams, fabrics, fibers, or other such fluid-absorbant materials). Operation 1777 describes causing the portion of the lytic material to be chemically deactivated (e.g. dispenser releasing protease nexin or other such plasminogen activator inhibitors). This can occur, for example, in a context in which a force apparently induced by a clot has been detectably reduced after module has dispensed a local dose of a plasminogen activator or other such lytic material. In some contexts, a quantity of the inhibitor released may be sufficient to deactivate at least 0.1% to 1% (or at most about 5% to 50%) of a released quantity of the plasminogen activator.
In light of teachings herein, and referring again to
Any of the above-described embodiments can likewise comprise a variant in which interface logic 140 invokes circuitry for performing operation 380 (of
Any of the above-described embodiments can likewise comprise a variant in which timing module 152 or another module 151 of response logic 155 performs operation 710 by responding to a signal from sensor 110 or some other indication that a lytic material will apparently be present in or near section 130 of lumen 195. This can occur, for example, in a context in which response logic 155 receives a notification that dispenser 119 has been activated. Alternatively or additionally, such indications may be received from one or more sensors 110 operable for detecting the lytic material directly or by detecting other such conditions as described herein. Alternatively or additionally, any of these modules or other components may likewise include a delay or other timing module 152 responsive to at least one of the one or more dispensation components. Alternatively or additionally, any of these modules or other components may likewise include one or more semi-permeable membranes 181.
Referring again to
Referring again to
Some or all of the embodiments described herein may generally comprise technologies for handling one or more bioactive agents and/or carriers in releasable module form, via a liquid-bearing conduit, in a mist or other spray form, in a pumped or other pressurized form, or otherwise according to technologies described herein. In a general sense, those skilled in the art will recognize that the various aspects described herein which can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or any combination thereof can be viewed as being composed of various types of “electrical circuitry.” Consequently, as used herein “electrical circuitry” includes, but is not limited to, electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of random access memory), and/or electrical circuitry forming a communications device (e.g., a modem, communications switch, or optical-electrical equipment). Those having skill in the art will recognize that the subject matter described herein may be implemented in an analog or digital fashion or some combination thereof.
Those skilled in the art will recognize that it is common within the art to describe devices and/or processes in the fashion set forth herein, and thereafter use engineering practices to integrate such described devices and/or processes into image processing systems. That is, at least a portion of the devices and/or processes described herein can be integrated into an image processing system via a reasonable amount of experimentation. Those having skill in the art will recognize that a typical image processing system generally includes one or more of a system unit housing, a video display device, a memory such as volatile and non-volatile memory, processors such as microprocessors and digital signal processors, computational entities such as operating systems, drivers, and applications programs, one or more interaction devices, such as a touch pad or screen, control systems including feedback loops and control motors (e.g., feedback for sensing lens position and/or velocity; control motors for moving/distorting lenses to give desired focuses. A typical image processing system may be implemented utilizing any suitable commercially available components, such as those typically found in digital still systems and/or digital motion systems.
Those skilled in the art will recognize that it is common within the art to describe devices and/or processes in the fashion set forth herein, and thereafter use engineering practices to integrate such described devices and/or processes into data processing systems. That is, at least a portion of the devices and/or processes described herein can be integrated into a data processing system via a reasonable amount of experimentation. Those having skill in the art will recognize that a typical data processing system generally includes one or more of a system unit housing, a video display device, a memory such as volatile and non-volatile memory, processors such as microprocessors and digital signal processors, computational entities such as operating systems, drivers, graphical user interfaces, and applications programs, one or more interaction devices, such as a touch pad or screen, and/or control systems including feedback loops and control motors (e.g., feedback for sensing position and/or velocity; control motors for moving and/or adjusting components and/or quantities). A typical data processing system may be implemented utilizing any suitable commercially available components, such as those typically found in data computing/communication and/or network computing/communication systems.
Those skilled in the art will recognize that it is common within the art to implement devices and/or processes and/or systems in the fashion(s) set forth herein, and thereafter use engineering and/or business practices to integrate such implemented devices and/or processes and/or systems into more comprehensive devices and/or processes and/or systems. That is, at least a portion of the devices and/or processes and/or systems described herein can be integrated into other devices and/or processes and/or systems via a reasonable amount of experimentation. Those having skill in the art will recognize that examples of such other devices and/or processes and/or systems might include—as appropriate to context and application—all or part of devices and/or processes and/or systems of (a) an air conveyance (e.g., an airplane, rocket, hovercraft, helicopter, etc.), (b) a ground conveyance (e.g., a car, truck, locomotive, tank, armored personnel carrier, etc.), (c) a building (e.g., a home, warehouse, office, etc.), (d) an appliance (e.g., a refrigerator, a washing machine, a dryer, etc.), (e) a communications system (e.g., a networked system, a telephone system, a Voice over IP system, etc.), (f) a business entity (e.g., an Internet Service Provider (ISP) entity such as Comcast Cable, Quest, Southwestern Bell, etc), or (g) a wired/wireless services entity such as Sprint, Cingular, Nextel, etc.), etc.
One skilled in the art will recognize that the herein described components (e.g., steps), devices, and objects and the discussion accompanying them are used as examples for the sake of conceptual clarity and that various configuration modifications are within the skill of those in the art. Consequently, as used herein, the specific exemplars set forth and the accompanying discussion are intended to be representative of their more general classes. In general, use of any specific exemplar herein is also intended to be representative of its class, and the non-inclusion of such specific components (e.g., steps), devices, and objects herein should not be taken as indicating that limitation is desired.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations are not expressly set forth herein for sake of clarity.
The herein described subject matter sometimes illustrates different components contained within, or connected with, different other components. It is to be understood that such depicted architectures are merely exemplary, and that in fact many other architectures can be implemented which achieve the same functionality. In a conceptual sense, any arrangement of components to achieve the same functionality is effectively “associated” such that the desired functionality is achieved. Hence, any two components herein combined to achieve a particular functionality can be seen as “associated with” each other such that the desired functionality is achieved, irrespective of architectures or intermedial components. Likewise, any two components so associated can also be viewed as being “operably connected”, or “operably coupled”, to each other to achieve the desired functionality, and any two components capable of being so associated can also be viewed as being “operably couplable”, to each other to achieve the desired functionality. Specific examples of operably couplable include but are not limited to physically mateable and/or physically interacting components and/or wirelessly interactable and/or wirelessly interacting components and/or logically interacting and/or logically interactable components.
While particular aspects of the present subject matter described herein have been shown and described, it will be apparent to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from the subject matter described herein and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of the subject matter described herein. Furthermore, it is to be understood that the invention is defined by the appended claims. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to inventions containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
With respect to the appended claims, those skilled in the art will appreciate that recited operations therein may generally be performed in any order. Examples of such alternate orderings may include overlapping, interleaved, interrupted, reordered, incremental, preparatory, supplemental, simultaneous, reverse, or other variant orderings, unless context dictates otherwise. With respect to context, even terms like “responsive to,” “related to,” or other past-tense adjectives are generally not intended to exclude such variants, unless context dictates otherwise.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
Number | Name | Date | Kind |
---|---|---|---|
3409008 | Mortensen et al. | Nov 1968 | A |
3623473 | Andersen et al. | Nov 1971 | A |
3673189 | Curran et al. | Jun 1972 | A |
3748503 | Cobarg et al. | Jul 1973 | A |
4039665 | Foley | Aug 1977 | A |
4138156 | Bonner | Feb 1979 | A |
4303984 | Houvig | Dec 1981 | A |
4312358 | Barney | Jan 1982 | A |
4314563 | Wheeler | Feb 1982 | A |
4321929 | Lemelson et al. | Mar 1982 | A |
4379461 | Nilsson et al. | Apr 1983 | A |
4536274 | Papadakis et al. | Aug 1985 | A |
4569355 | Bitterly | Feb 1986 | A |
4629336 | Ishizaka | Dec 1986 | A |
4649933 | Jackson | Mar 1987 | A |
4689041 | Corday et al. | Aug 1987 | A |
4756310 | Bitterly | Jul 1988 | A |
4804054 | Howson et al. | Feb 1989 | A |
4819658 | Kolodner | Apr 1989 | A |
4820261 | Schmoll et al. | Apr 1989 | A |
4857998 | Tsujihara et al. | Aug 1989 | A |
4860751 | Callaghan | Aug 1989 | A |
4981596 | Shiino et al. | Jan 1991 | A |
5012411 | Policastro et al. | Apr 1991 | A |
5036462 | Kaufman et al. | Jul 1991 | A |
5103827 | Smith | Apr 1992 | A |
5153827 | Coutré et al. | Oct 1992 | A |
5163905 | Don Michael | Nov 1992 | A |
5178153 | Einzig | Jan 1993 | A |
5188106 | Nappholz et al. | Feb 1993 | A |
5201318 | Rava et al. | Apr 1993 | A |
5242382 | Gorsuch et al. | Sep 1993 | A |
5243998 | Silverman et al. | Sep 1993 | A |
5256538 | Aiken et al. | Oct 1993 | A |
5262669 | Wakatabe et al. | Nov 1993 | A |
5282467 | Piantadosi et al. | Feb 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5335313 | Douglas | Aug 1994 | A |
5348002 | Caro | Sep 1994 | A |
5348015 | Moehring et al. | Sep 1994 | A |
5360005 | Wilk | Nov 1994 | A |
5409009 | Olson | Apr 1995 | A |
5429137 | Phelps et al. | Jul 1995 | A |
5438983 | Falcone | Aug 1995 | A |
5441051 | Hileman et al. | Aug 1995 | A |
5443440 | Tumey et al. | Aug 1995 | A |
5445616 | Kratoska et al. | Aug 1995 | A |
5474574 | Payne et al. | Dec 1995 | A |
5497787 | Nemesdy et al. | Mar 1996 | A |
5508203 | Fuller et al. | Apr 1996 | A |
5524636 | Sarvazyan et al. | Jun 1996 | A |
5546955 | Wilk | Aug 1996 | A |
5558638 | Evers et al. | Sep 1996 | A |
5569215 | Crocker | Oct 1996 | A |
5573002 | Pratt | Nov 1996 | A |
5576952 | Stutman et al. | Nov 1996 | A |
5590650 | Genova | Jan 1997 | A |
5593431 | Sheldon | Jan 1997 | A |
5601811 | Gallagher et al. | Feb 1997 | A |
5620475 | Magnusson | Apr 1997 | A |
5628322 | Mine | May 1997 | A |
5662109 | Hutson | Sep 1997 | A |
5671750 | Shinoda | Sep 1997 | A |
5684460 | Scanlon | Nov 1997 | A |
5699934 | Kolcun et al. | Dec 1997 | A |
5713858 | Heruth et al. | Feb 1998 | A |
5718247 | Frankel | Feb 1998 | A |
5722972 | Power et al. | Mar 1998 | A |
5724983 | Selker et al. | Mar 1998 | A |
5725492 | Igo et al. | Mar 1998 | A |
5740540 | Emmermann | Apr 1998 | A |
5755571 | Companion | May 1998 | A |
5755741 | Vogel | May 1998 | A |
5769801 | Tumey et al. | Jun 1998 | A |
5793969 | Kamentsky et al. | Aug 1998 | A |
5795327 | Wilson et al. | Aug 1998 | A |
5807261 | Benaron et al. | Sep 1998 | A |
5832182 | Zhang et al. | Nov 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5840049 | Tumey et al. | Nov 1998 | A |
5857998 | Barry | Jan 1999 | A |
5865749 | Doten et al. | Feb 1999 | A |
5879292 | Sternberg et al. | Mar 1999 | A |
5886142 | Thakur et al. | Mar 1999 | A |
5891065 | Cariapa et al. | Apr 1999 | A |
5892570 | Stevens | Apr 1999 | A |
5911689 | Smith et al. | Jun 1999 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5928185 | Muller et al. | Jul 1999 | A |
5931797 | Tumey et al. | Aug 1999 | A |
5935075 | Casscells et al. | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5941829 | Saltzstein et al. | Aug 1999 | A |
5942986 | Shabot et al. | Aug 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5963997 | Hagopian | Oct 1999 | A |
5967986 | Cimochowski et al. | Oct 1999 | A |
5978693 | Hamilton et al. | Nov 1999 | A |
5983429 | Stacy et al. | Nov 1999 | A |
5987345 | Engelmann et al. | Nov 1999 | A |
5989194 | Davenport et al. | Nov 1999 | A |
5989245 | Prescott | Nov 1999 | A |
5991654 | Tumey et al. | Nov 1999 | A |
5991694 | Gudat et al. | Nov 1999 | A |
5993400 | Rincoe et al. | Nov 1999 | A |
5997472 | Bonnell et al. | Dec 1999 | A |
5999836 | Nelson et al. | Dec 1999 | A |
5999842 | Harrison et al. | Dec 1999 | A |
6014346 | Malone | Jan 2000 | A |
6014626 | Cohen | Jan 2000 | A |
6015387 | Schwartz et al. | Jan 2000 | A |
6019729 | Itoigawa et al. | Feb 2000 | A |
6023637 | Liu et al. | Feb 2000 | A |
6025128 | Veltri et al. | Feb 2000 | A |
6033364 | Ohman et al. | Mar 2000 | A |
6034526 | Montant et al. | Mar 2000 | A |
6035230 | Kang et al. | Mar 2000 | A |
6047201 | Jackson, III | Apr 2000 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6056692 | Schwartz | May 2000 | A |
6063044 | Leonard et al. | May 2000 | A |
6064770 | Scarth et al. | May 2000 | A |
6069696 | McQueen et al. | May 2000 | A |
6071956 | Slepian et al. | Jun 2000 | A |
6075755 | Zarchan | Jun 2000 | A |
6077256 | Mann | Jun 2000 | A |
6081741 | Hollis | Jun 2000 | A |
6084174 | Hedengren et al. | Jul 2000 | A |
6086247 | von Hollen | Jul 2000 | A |
6098908 | Ng | Aug 2000 | A |
6117077 | Del Mar et al. | Sep 2000 | A |
6117087 | Kamm et al. | Sep 2000 | A |
6121002 | Robins | Sep 2000 | A |
6124597 | Shehada et al. | Sep 2000 | A |
6126614 | Jenkins et al. | Oct 2000 | A |
6133837 | Riley | Oct 2000 | A |
6137527 | Abdel-Malek et al. | Oct 2000 | A |
6139495 | De La Huerga | Oct 2000 | A |
6139499 | Wilk | Oct 2000 | A |
6146358 | Rowe | Nov 2000 | A |
6149674 | Borders | Nov 2000 | A |
6152881 | Raines et al. | Nov 2000 | A |
6161041 | Stoop et al. | Dec 2000 | A |
6165151 | Weiner | Dec 2000 | A |
6165787 | Crabtree et al. | Dec 2000 | A |
6168563 | Brown | Jan 2001 | B1 |
6170997 | Glew et al. | Jan 2001 | B1 |
6177873 | Cragun | Jan 2001 | B1 |
6179786 | Young | Jan 2001 | B1 |
6179793 | Rothman et al. | Jan 2001 | B1 |
6186962 | Lloyd et al. | Feb 2001 | B1 |
6190313 | Hinkle | Feb 2001 | B1 |
6192143 | Souluer | Feb 2001 | B1 |
6193669 | Degany et al. | Feb 2001 | B1 |
6195571 | Osuge | Feb 2001 | B1 |
6196973 | Lazenby et al. | Mar 2001 | B1 |
6197345 | Porter | Mar 2001 | B1 |
6200270 | Biehl et al. | Mar 2001 | B1 |
6206835 | Spillman, Jr. et al. | Mar 2001 | B1 |
6210301 | Abraham-Fuchs et al. | Apr 2001 | B1 |
6216066 | Goebel et al. | Apr 2001 | B1 |
6217554 | Green | Apr 2001 | B1 |
6217846 | Stuttle | Apr 2001 | B1 |
6219929 | Tasker et al. | Apr 2001 | B1 |
6228034 | Voss et al. | May 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6231532 | Watson et al. | May 2001 | B1 |
6231591 | Desai | May 2001 | B1 |
6233479 | Haddad et al. | May 2001 | B1 |
6233487 | Mika et al. | May 2001 | B1 |
6238349 | Hickey | May 2001 | B1 |
6238354 | Alvarez | May 2001 | B1 |
6240582 | Reinke | Jun 2001 | B1 |
6241661 | Schluess et al. | Jun 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6258046 | Kimball et al. | Jul 2001 | B1 |
6261249 | Talish et al. | Jul 2001 | B1 |
6263243 | Lang | Jul 2001 | B1 |
6267728 | Hayden | Jul 2001 | B1 |
6268161 | Han et al. | Jul 2001 | B1 |
6269376 | Dhillon et al. | Jul 2001 | B1 |
6270463 | Morris, Sr. et al. | Aug 2001 | B1 |
6271618 | Hoffmann et al. | Aug 2001 | B1 |
6271766 | Didden et al. | Aug 2001 | B1 |
6272367 | Chance | Aug 2001 | B1 |
6275733 | Park et al. | Aug 2001 | B1 |
6277071 | Hennessy et al. | Aug 2001 | B1 |
6280390 | Akselrod et al. | Aug 2001 | B1 |
6282441 | Raymond et al. | Aug 2001 | B1 |
6282448 | Katz et al. | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6287608 | Levin et al. | Sep 2001 | B1 |
6292685 | Pompei | Sep 2001 | B1 |
6299347 | Pompei | Oct 2001 | B1 |
6300085 | Alkon | Oct 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6305377 | Portwood et al. | Oct 2001 | B1 |
6312378 | Bardy | Nov 2001 | B1 |
6317731 | Luciano | Nov 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6332502 | Mills et al. | Dec 2001 | B1 |
6336900 | Alleckson et al. | Jan 2002 | B1 |
6336903 | Bardy | Jan 2002 | B1 |
6338719 | Drzewiecki et al. | Jan 2002 | B1 |
6340928 | McCurdy | Jan 2002 | B1 |
6352502 | Chaiken et al. | Mar 2002 | B1 |
6354999 | Dgany et al. | Mar 2002 | B1 |
6355000 | Ogura | Mar 2002 | B1 |
6358201 | Childre et al. | Mar 2002 | B1 |
6358219 | Arkans | Mar 2002 | B1 |
6361495 | Grolman | Mar 2002 | B1 |
6363270 | Colla et al. | Mar 2002 | B1 |
6377834 | Zhou et al. | Apr 2002 | B1 |
6382568 | Snell | May 2002 | B1 |
6383136 | Jordan | May 2002 | B1 |
6383137 | Berry | May 2002 | B1 |
6384627 | Fross et al. | May 2002 | B1 |
6385332 | Zahalka et al. | May 2002 | B1 |
6387048 | Schulman et al. | May 2002 | B1 |
6387059 | Marchitto et al. | May 2002 | B1 |
6393315 | Aprahamian et al. | May 2002 | B1 |
6402371 | Pompei et al. | Jun 2002 | B2 |
6409662 | Lloyd et al. | Jun 2002 | B1 |
6409674 | Brockway et al. | Jun 2002 | B1 |
6413223 | Yang et al. | Jul 2002 | B1 |
6413233 | Sites et al. | Jul 2002 | B1 |
6416471 | Kumar et al. | Jul 2002 | B1 |
6425866 | Brucher et al. | Jul 2002 | B1 |
6425875 | Reifman et al. | Jul 2002 | B1 |
6430430 | Gosche | Aug 2002 | B1 |
6438216 | Aktas | Aug 2002 | B1 |
6440067 | DeLuca et al. | Aug 2002 | B1 |
6440084 | Gentempo et al. | Aug 2002 | B1 |
6440090 | Schallhorn | Aug 2002 | B1 |
6441747 | Khair et al. | Aug 2002 | B1 |
6442241 | Tsumpes | Aug 2002 | B1 |
6442421 | Le Van Quyen et al. | Aug 2002 | B1 |
6445183 | Shimizu et al. | Sep 2002 | B1 |
6445945 | Arsenault | Sep 2002 | B1 |
6447455 | Bang et al. | Sep 2002 | B2 |
6447460 | Zheng et al. | Sep 2002 | B1 |
6450027 | Hogfors et al. | Sep 2002 | B1 |
6454705 | Cosentino et al. | Sep 2002 | B1 |
6454707 | Casscells, III et al. | Sep 2002 | B1 |
6454718 | Clift | Sep 2002 | B1 |
6455243 | Jeejeebhoy | Sep 2002 | B1 |
6458150 | Evans et al. | Oct 2002 | B1 |
6459929 | Hopper et al. | Oct 2002 | B1 |
6461303 | Angelsen | Oct 2002 | B2 |
6463310 | Swedlow et al. | Oct 2002 | B1 |
6464646 | Shalom et al. | Oct 2002 | B1 |
6468219 | Njemanze | Oct 2002 | B1 |
6468234 | Van der Loos et al. | Oct 2002 | B1 |
6468242 | Wilson et al. | Oct 2002 | B1 |
6473708 | Watkins et al. | Oct 2002 | B1 |
6475155 | Ogura et al. | Nov 2002 | B2 |
6475159 | Casscells et al. | Nov 2002 | B1 |
6475170 | Doron et al. | Nov 2002 | B1 |
6478737 | Bardy | Nov 2002 | B2 |
6478757 | Barak | Nov 2002 | B1 |
6482197 | Finch et al. | Nov 2002 | B2 |
6484047 | Vilsmeier | Nov 2002 | B1 |
6485416 | Platt et al. | Nov 2002 | B1 |
6487507 | Mansfield et al. | Nov 2002 | B1 |
6490490 | Uchikubo et al. | Dec 2002 | B1 |
6497222 | Bolz et al. | Dec 2002 | B2 |
6501849 | Gupta et al. | Dec 2002 | B1 |
6505196 | Drucker et al. | Jan 2003 | B2 |
6506153 | Littek et al. | Jan 2003 | B1 |
6506437 | Harish et al. | Jan 2003 | B1 |
6507663 | Souluer | Jan 2003 | B2 |
6507747 | Gowda et al. | Jan 2003 | B1 |
6507754 | Le Van Quyen et al. | Jan 2003 | B2 |
6509747 | Nagai et al. | Jan 2003 | B2 |
6511477 | Altman et al. | Jan 2003 | B2 |
6512456 | Taylor, Jr. | Jan 2003 | B1 |
6513026 | Horvitz et al. | Jan 2003 | B1 |
6514195 | Ferek-Petric | Feb 2003 | B1 |
6514226 | Levin et al. | Feb 2003 | B1 |
6518016 | Bertina et al. | Feb 2003 | B1 |
6520919 | Nunome et al. | Feb 2003 | B1 |
6525712 | Held | Feb 2003 | B1 |
6529757 | Patel et al. | Mar 2003 | B1 |
6529759 | Tucker et al. | Mar 2003 | B1 |
6533724 | McNair | Mar 2003 | B2 |
6536949 | Heuser | Mar 2003 | B1 |
6537228 | Lambert | Mar 2003 | B1 |
6539302 | Bender et al. | Mar 2003 | B1 |
6540668 | Schulz et al. | Apr 2003 | B1 |
6542767 | McNichols et al. | Apr 2003 | B1 |
6544180 | Doten et al. | Apr 2003 | B1 |
6544186 | Shelby et al. | Apr 2003 | B1 |
6544202 | McEwen et al. | Apr 2003 | B2 |
6545603 | Launay et al. | Apr 2003 | B1 |
6547736 | Moehring et al. | Apr 2003 | B1 |
6547746 | Marino | Apr 2003 | B1 |
6547749 | Hansen | Apr 2003 | B2 |
6551306 | Carriazo | Apr 2003 | B1 |
6552531 | Fey et al. | Apr 2003 | B1 |
6554819 | Reich | Apr 2003 | B2 |
6559769 | Anthony et al. | May 2003 | B2 |
6560804 | Wise et al. | May 2003 | B2 |
6561996 | Gorsuch | May 2003 | B1 |
6567705 | Stokes et al. | May 2003 | B1 |
6569095 | Eggers | May 2003 | B2 |
6573063 | Hochman | Jun 2003 | B2 |
6577901 | Thompson | Jun 2003 | B2 |
6579242 | Bui et al. | Jun 2003 | B2 |
6580016 | Teirstein et al. | Jun 2003 | B2 |
6580994 | Katayama et al. | Jun 2003 | B2 |
6582379 | Stisen | Jun 2003 | B1 |
6583411 | Altmann et al. | Jun 2003 | B1 |
6584345 | Govari | Jun 2003 | B2 |
6584628 | Kummer et al. | Jul 2003 | B1 |
6584931 | Kall et al. | Jul 2003 | B1 |
6585328 | Oexman et al. | Jul 2003 | B1 |
6585763 | Keilman et al. | Jul 2003 | B1 |
6591182 | Cece et al. | Jul 2003 | B1 |
6592567 | Levin et al. | Jul 2003 | B1 |
6594518 | Benaron et al. | Jul 2003 | B1 |
6597940 | Bishop et al. | Jul 2003 | B2 |
6597948 | Rockwell et al. | Jul 2003 | B1 |
6600425 | Parsadayan | Jul 2003 | B1 |
6600949 | Turcott | Jul 2003 | B1 |
6604650 | Sagar | Aug 2003 | B2 |
6606579 | Gu | Aug 2003 | B1 |
6610024 | Benatti | Aug 2003 | B1 |
6611846 | Stoodley | Aug 2003 | B1 |
6612982 | Ouchi | Sep 2003 | B1 |
6615071 | Casscells, III et al. | Sep 2003 | B1 |
6616606 | Petersen et al. | Sep 2003 | B1 |
6616611 | Moehring | Sep 2003 | B1 |
6616613 | Goodman | Sep 2003 | B1 |
6620115 | Sarvazyan et al. | Sep 2003 | B2 |
6620146 | Gibbs | Sep 2003 | B2 |
6621506 | Burbidge | Sep 2003 | B2 |
6621918 | Hu et al. | Sep 2003 | B1 |
6625252 | Mirabella | Sep 2003 | B2 |
6626840 | Drzewiecki et al. | Sep 2003 | B2 |
6629937 | Watrous | Oct 2003 | B2 |
6631287 | Newman et al. | Oct 2003 | B2 |
6635017 | Moehring et al. | Oct 2003 | B1 |
6635027 | Cragg et al. | Oct 2003 | B1 |
6635049 | Robinson et al. | Oct 2003 | B1 |
6636621 | Thebaud | Oct 2003 | B2 |
6636755 | Toida | Oct 2003 | B2 |
6638218 | Bulat | Oct 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6643646 | Su et al. | Nov 2003 | B2 |
6645165 | Waldridge et al. | Nov 2003 | B2 |
6645192 | Kenison et al. | Nov 2003 | B2 |
6646556 | Smith et al. | Nov 2003 | B1 |
6647093 | Schmitz et al. | Nov 2003 | B2 |
6652465 | Ogura | Nov 2003 | B2 |
6658292 | Kroll et al. | Dec 2003 | B2 |
6659327 | Heck et al. | Dec 2003 | B2 |
6660028 | Magers et al. | Dec 2003 | B2 |
6663242 | Davenport | Dec 2003 | B1 |
6668188 | Sun et al. | Dec 2003 | B2 |
6671529 | Claure et al. | Dec 2003 | B2 |
6671540 | Hochman | Dec 2003 | B1 |
6671541 | Bishop et al. | Dec 2003 | B2 |
6671547 | Lyster et al. | Dec 2003 | B2 |
6672307 | McDonald et al. | Jan 2004 | B2 |
6673561 | Morris | Jan 2004 | B1 |
6675040 | Cosman | Jan 2004 | B1 |
6676608 | Keren | Jan 2004 | B1 |
6679830 | Kolarovic et al. | Jan 2004 | B2 |
6682483 | Abend et al. | Jan 2004 | B1 |
6682490 | Roy et al. | Jan 2004 | B2 |
6685303 | Trauernicht et al. | Feb 2004 | B1 |
6687230 | Furutono et al. | Feb 2004 | B1 |
6687544 | Levine et al. | Feb 2004 | B1 |
6689069 | Bratteli et al. | Feb 2004 | B2 |
6689612 | Samsoondar | Feb 2004 | B2 |
6689974 | Guillot et al. | Feb 2004 | B2 |
6690267 | Linden et al. | Feb 2004 | B2 |
6691979 | Parsons et al. | Feb 2004 | B2 |
6694176 | Tsujita et al. | Feb 2004 | B1 |
6694177 | Eggers et al. | Feb 2004 | B2 |
6699231 | Sterman et al. | Mar 2004 | B1 |
6706001 | Fresco | Mar 2004 | B2 |
6706013 | Bhat et al. | Mar 2004 | B1 |
6709444 | Makower | Mar 2004 | B1 |
6711436 | Duhaylongsod | Mar 2004 | B1 |
6715402 | Pfaff et al. | Apr 2004 | B2 |
6717337 | Howarth et al. | Apr 2004 | B2 |
6720712 | Scott et al. | Apr 2004 | B2 |
6720875 | Philippe | Apr 2004 | B2 |
6721980 | Price et al. | Apr 2004 | B1 |
6731976 | Penn et al. | May 2004 | B2 |
6732884 | Topliffe et al. | May 2004 | B2 |
6733447 | Lai et al. | May 2004 | B2 |
6733461 | Bratteli | May 2004 | B2 |
6735331 | Binnun et al. | May 2004 | B1 |
6736790 | Barbut et al. | May 2004 | B2 |
6738655 | Sen et al. | May 2004 | B1 |
6738769 | Sharp | May 2004 | B2 |
6740042 | Lerner et al. | May 2004 | B1 |
6740045 | Amano | May 2004 | B2 |
6740076 | Hoben et al. | May 2004 | B2 |
6748929 | Przymusinski et al. | Jun 2004 | B2 |
6749619 | Ouriel et al. | Jun 2004 | B2 |
6751255 | Reuven et al. | Jun 2004 | B1 |
6752771 | Rothman et al. | Jun 2004 | B2 |
6755783 | Cosentino et al. | Jun 2004 | B2 |
6757412 | Parsons et al. | Jun 2004 | B1 |
6763261 | Casscells, III et al. | Jul 2004 | B2 |
6763262 | Hohla et al. | Jul 2004 | B2 |
6770045 | Naft et al. | Aug 2004 | B2 |
6773404 | Poezevera et al. | Aug 2004 | B2 |
6776756 | Feldon et al. | Aug 2004 | B2 |
6783492 | Dominguez et al. | Aug 2004 | B2 |
6785358 | Johnson et al. | Aug 2004 | B2 |
6786879 | Bolam et al. | Sep 2004 | B1 |
6790204 | Zadno-Azizi et al. | Sep 2004 | B2 |
6791460 | Dixon et al. | Sep 2004 | B2 |
6793625 | Cavallaro et al. | Sep 2004 | B2 |
6798226 | Altmann et al. | Sep 2004 | B2 |
6801137 | Eggers | Oct 2004 | B2 |
6802811 | Slepian | Oct 2004 | B1 |
6804654 | Kobylevsky et al. | Oct 2004 | B2 |
6809653 | Mann et al. | Oct 2004 | B1 |
6810876 | Berthon-Jones | Nov 2004 | B2 |
6813009 | Riordan et al. | Nov 2004 | B2 |
6816743 | Moreno et al. | Nov 2004 | B2 |
6816744 | Garfield et al. | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6822571 | Conway | Nov 2004 | B2 |
6824512 | Warkentin et al. | Nov 2004 | B2 |
6826578 | Brackett et al. | Nov 2004 | B2 |
6830549 | Bui et al. | Dec 2004 | B2 |
6830577 | Nash et al. | Dec 2004 | B2 |
6834306 | Tsimelzon | Dec 2004 | B1 |
6835351 | Huber et al. | Dec 2004 | B2 |
6835553 | Han et al. | Dec 2004 | B2 |
6836528 | Reddy et al. | Dec 2004 | B2 |
6837351 | Showalter et al. | Jan 2005 | B2 |
6839455 | Kaufman | Jan 2005 | B2 |
6840117 | Hubbard, Jr. | Jan 2005 | B2 |
6843772 | Nunome et al. | Jan 2005 | B2 |
6843774 | Foust et al. | Jan 2005 | B2 |
6845146 | Rick et al. | Jan 2005 | B2 |
6847841 | El Hatw | Jan 2005 | B1 |
6847913 | Wigley et al. | Jan 2005 | B2 |
6852089 | Kloecker et al. | Feb 2005 | B2 |
6852132 | Houser et al. | Feb 2005 | B1 |
6854459 | Cox | Feb 2005 | B1 |
6856831 | Griffin et al. | Feb 2005 | B2 |
6871214 | Parsons et al. | Mar 2005 | B2 |
6878111 | Kenknight et al. | Apr 2005 | B2 |
6878117 | Watrous | Apr 2005 | B1 |
6878518 | Whitehead | Apr 2005 | B2 |
6880387 | Kessler et al. | Apr 2005 | B2 |
6881192 | Park | Apr 2005 | B1 |
6885882 | Cote et al. | Apr 2005 | B2 |
6886002 | Horvitz | Apr 2005 | B2 |
6886200 | Blyshak et al. | May 2005 | B2 |
6887201 | Bardy | May 2005 | B2 |
6892405 | Dimitriu et al. | May 2005 | B1 |
6893089 | McMillen et al. | May 2005 | B2 |
6893396 | Schulze et al. | May 2005 | B2 |
6895265 | Silver | May 2005 | B2 |
6898457 | Kraus et al. | May 2005 | B1 |
6898585 | Benson et al. | May 2005 | B2 |
6902576 | Drasler et al. | Jun 2005 | B2 |
6905505 | Nash et al. | Jun 2005 | B2 |
6907375 | Guggari et al. | Jun 2005 | B2 |
6908431 | Bardy | Jun 2005 | B2 |
6908437 | Bardy | Jun 2005 | B2 |
6916424 | Collins et al. | Jul 2005 | B2 |
6921365 | Lee | Jul 2005 | B2 |
6922592 | Thompson et al. | Jul 2005 | B2 |
6922664 | Fernandez et al. | Jul 2005 | B1 |
6923771 | Ogura et al. | Aug 2005 | B2 |
6925621 | Mielke et al. | Aug 2005 | B2 |
6926668 | Bardy | Aug 2005 | B2 |
6929922 | Connor et al. | Aug 2005 | B1 |
6932091 | Frazier et al. | Aug 2005 | B2 |
6934579 | Mantzaridis et al. | Aug 2005 | B2 |
6936025 | Evans et al. | Aug 2005 | B1 |
6939304 | Schnall et al. | Sep 2005 | B2 |
6939322 | Crank et al. | Sep 2005 | B2 |
6942616 | Kerr, III | Sep 2005 | B2 |
6942626 | Salisbury et al. | Sep 2005 | B2 |
6943574 | Altmann et al. | Sep 2005 | B2 |
6944497 | Stypulkowski | Sep 2005 | B2 |
6945944 | Kuiper et al. | Sep 2005 | B2 |
6947780 | Scharf | Sep 2005 | B2 |
6947781 | Asada et al. | Sep 2005 | B2 |
6949075 | Hatlesad et al. | Sep 2005 | B2 |
6950692 | Gelikonov et al. | Sep 2005 | B2 |
6950693 | Wehberg | Sep 2005 | B1 |
6953666 | Kinkade, Jr. et al. | Oct 2005 | B1 |
6955113 | Demers | Oct 2005 | B2 |
6959211 | Rule et al. | Oct 2005 | B2 |
6961327 | Niu | Nov 2005 | B2 |
6961971 | Schneider et al. | Nov 2005 | B2 |
6963772 | Bloom et al. | Nov 2005 | B2 |
6966557 | Kirk et al. | Nov 2005 | B2 |
6966650 | Hu et al. | Nov 2005 | B2 |
6968294 | Gutta et al. | Nov 2005 | B2 |
6968375 | Brown | Nov 2005 | B1 |
6969345 | Jassawalla et al. | Nov 2005 | B2 |
6969355 | Narimatsu | Nov 2005 | B2 |
6970737 | Brodnick et al. | Nov 2005 | B1 |
6970847 | Melen et al. | Nov 2005 | B1 |
6972122 | Haroon et al. | Dec 2005 | B2 |
6974463 | Magers et al. | Dec 2005 | B2 |
6974567 | Edwards et al. | Dec 2005 | B2 |
6975232 | McKenna | Dec 2005 | B1 |
6975898 | Seibel | Dec 2005 | B2 |
6978169 | Guerra | Dec 2005 | B1 |
6978182 | Mazar et al. | Dec 2005 | B2 |
6979293 | Hansmann et al. | Dec 2005 | B2 |
6980851 | Zhu et al. | Dec 2005 | B2 |
6980852 | Jersey-Willuhn et al. | Dec 2005 | B2 |
6983178 | Fine et al. | Jan 2006 | B2 |
6984207 | Sullivan et al. | Jan 2006 | B1 |
6984373 | Wescott et al. | Jan 2006 | B2 |
6988088 | Miikkulainen et al. | Jan 2006 | B1 |
6988499 | Holt et al. | Jan 2006 | B2 |
6990365 | Parker et al. | Jan 2006 | B1 |
6990371 | Powers et al. | Jan 2006 | B2 |
6990455 | Vozick et al. | Jan 2006 | B2 |
6990980 | Richey, II | Jan 2006 | B2 |
6993167 | Skladnev et al. | Jan 2006 | B1 |
6993380 | Modarres | Jan 2006 | B1 |
6993382 | Casscells et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
6999812 | Kawada et al. | Feb 2006 | B2 |
7001338 | Hayek et al. | Feb 2006 | B2 |
7003340 | Say et al. | Feb 2006 | B2 |
7003525 | Horvitz et al. | Feb 2006 | B1 |
7004907 | Banet et al. | Feb 2006 | B2 |
7004910 | Lindsey | Feb 2006 | B2 |
7004911 | Tu et al. | Feb 2006 | B1 |
7006676 | Zeylikovich et al. | Feb 2006 | B1 |
7006858 | Silver et al. | Feb 2006 | B2 |
7006861 | Flock et al. | Feb 2006 | B2 |
7011633 | Strandberg | Mar 2006 | B2 |
7011645 | McGuckin, Jr. et al. | Mar 2006 | B2 |
7014861 | Roorda et al. | Mar 2006 | B2 |
7016021 | Nakajima et al. | Mar 2006 | B2 |
7016467 | Brooks | Mar 2006 | B2 |
7016601 | Yoneya et al. | Mar 2006 | B1 |
7020666 | Doise et al. | Mar 2006 | B2 |
7024234 | Margulies et al. | Apr 2006 | B2 |
7025778 | Hayashi et al. | Apr 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7029447 | Rantala | Apr 2006 | B2 |
7030764 | Smith et al. | Apr 2006 | B2 |
7033776 | Toombs | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7037256 | Osbon et al. | May 2006 | B2 |
7037273 | Zhu et al. | May 2006 | B2 |
7038595 | Seely | May 2006 | B2 |
7039698 | Slemmer et al. | May 2006 | B2 |
7041079 | Yozu et al. | May 2006 | B2 |
7043288 | Davis, III et al. | May 2006 | B2 |
7047083 | Gunderson et al. | May 2006 | B2 |
7047149 | Maki et al. | May 2006 | B1 |
7051738 | Oron et al. | May 2006 | B2 |
7052427 | Kapaan et al. | May 2006 | B2 |
7052474 | Castell et al. | May 2006 | B2 |
7058450 | Struble et al. | Jun 2006 | B2 |
7062528 | Deguchi | Jun 2006 | B2 |
7065465 | Chen et al. | Jun 2006 | B2 |
7066873 | Hughett et al. | Jun 2006 | B2 |
7069086 | Von Arx | Jun 2006 | B2 |
7072711 | Girouard et al. | Jul 2006 | B2 |
7074188 | Nair et al. | Jul 2006 | B2 |
7074426 | Kochinke | Jul 2006 | B2 |
7076436 | Ross, Jr. et al. | Jul 2006 | B1 |
7077809 | Wu et al. | Jul 2006 | B2 |
7079035 | Bock et al. | Jul 2006 | B2 |
7087395 | Garrity et al. | Aug 2006 | B1 |
7087903 | Balan et al. | Aug 2006 | B2 |
7088993 | Dumont et al. | Aug 2006 | B2 |
7092970 | Shiibashi et al. | Aug 2006 | B2 |
7097625 | Steinberg | Aug 2006 | B2 |
7098673 | Launay et al. | Aug 2006 | B2 |
7098678 | Altmann et al. | Aug 2006 | B2 |
7100491 | Yatsko et al. | Sep 2006 | B2 |
7104955 | Bardy | Sep 2006 | B2 |
7107096 | Fischell et al. | Sep 2006 | B2 |
7108686 | Burke et al. | Sep 2006 | B2 |
7110806 | Prince | Sep 2006 | B2 |
7112318 | Madar et al. | Sep 2006 | B2 |
7113819 | Hamilton et al. | Sep 2006 | B2 |
7115097 | Johnson | Oct 2006 | B2 |
7116655 | Yegoshin | Oct 2006 | B2 |
7116825 | Lee et al. | Oct 2006 | B2 |
7117036 | Florio | Oct 2006 | B2 |
7117037 | Hiebert et al. | Oct 2006 | B2 |
7122005 | Shusterman | Oct 2006 | B2 |
7122019 | Kesten et al. | Oct 2006 | B1 |
7123950 | Mannheimer | Oct 2006 | B2 |
7124837 | Martin et al. | Oct 2006 | B2 |
7127370 | Kelly, Jr. et al. | Oct 2006 | B2 |
7128713 | Moehring et al. | Oct 2006 | B2 |
7130396 | Rogers et al. | Oct 2006 | B2 |
7133661 | Hatae et al. | Nov 2006 | B2 |
7134157 | Koch | Nov 2006 | B2 |
7135007 | Scott et al. | Nov 2006 | B2 |
7135032 | Akerfeldt | Nov 2006 | B2 |
7136357 | Soumiya et al. | Nov 2006 | B2 |
7136704 | Schulman | Nov 2006 | B2 |
7138902 | Menard | Nov 2006 | B2 |
7142632 | Atzinger et al. | Nov 2006 | B2 |
7143222 | Fisher et al. | Nov 2006 | B2 |
7144099 | Cabal et al. | Dec 2006 | B2 |
7146664 | Grosvenor | Dec 2006 | B1 |
7147600 | Bardy | Dec 2006 | B2 |
7149645 | Mangrulkar et al. | Dec 2006 | B2 |
7151957 | Beker et al. | Dec 2006 | B2 |
7155273 | Taylor | Dec 2006 | B2 |
7155281 | Fayram | Dec 2006 | B1 |
7155729 | Andrew et al. | Dec 2006 | B1 |
7158692 | Chalana et al. | Jan 2007 | B2 |
7158861 | Wang et al. | Jan 2007 | B2 |
7162061 | Takeo | Jan 2007 | B1 |
7162062 | Breitenstein et al. | Jan 2007 | B2 |
7162068 | Akagi | Jan 2007 | B2 |
7163520 | Bernard et al. | Jan 2007 | B2 |
7164941 | Misczynski et al. | Jan 2007 | B2 |
7164948 | Struble et al. | Jan 2007 | B2 |
7167734 | Khalil et al. | Jan 2007 | B2 |
7171251 | Sarussi et al. | Jan 2007 | B2 |
7171680 | Lange | Jan 2007 | B2 |
7172493 | Novak et al. | Feb 2007 | B2 |
7174005 | Rodkey et al. | Feb 2007 | B1 |
7177699 | Fabian et al. | Feb 2007 | B2 |
7179251 | Palasis | Feb 2007 | B2 |
7180415 | Bankert et al. | Feb 2007 | B2 |
7180983 | Uchida et al. | Feb 2007 | B2 |
7181054 | Zaleski | Feb 2007 | B2 |
7183057 | Benson | Feb 2007 | B2 |
7184580 | Hamid | Feb 2007 | B2 |
7184820 | Jersey-Willuhn et al. | Feb 2007 | B2 |
7187960 | Abreu | Mar 2007 | B2 |
7189204 | Ni et al. | Mar 2007 | B2 |
7190987 | Lindekugel et al. | Mar 2007 | B2 |
7190996 | Jarverud | Mar 2007 | B2 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7192726 | Carr, Jr. et al. | Mar 2007 | B1 |
7195598 | Fuchs et al. | Mar 2007 | B2 |
7195640 | Falotico et al. | Mar 2007 | B2 |
7196620 | Nanba | Mar 2007 | B2 |
7198603 | Penner et al. | Apr 2007 | B2 |
7199494 | Rapp et al. | Apr 2007 | B2 |
7200431 | Franco et al. | Apr 2007 | B2 |
7200682 | Miyazaki et al. | Apr 2007 | B2 |
7202844 | Nakamigawa | Apr 2007 | B2 |
7203294 | Carnazza et al. | Apr 2007 | B2 |
7205991 | Fitzmaurice et al. | Apr 2007 | B2 |
7207939 | Husher | Apr 2007 | B2 |
7208983 | Imaizumi et al. | Apr 2007 | B2 |
7209671 | Hayee et al. | Apr 2007 | B1 |
7209955 | Major et al. | Apr 2007 | B1 |
7211048 | Najafi et | May 2007 | B1 |
7211063 | Tom | May 2007 | B2 |
7212111 | Tupler et al. | May 2007 | B2 |
7213009 | Pestotnik et al. | May 2007 | B2 |
7214094 | Kaminski et al. | May 2007 | B2 |
7214191 | Stringer et al. | May 2007 | B2 |
7214193 | Freund et al. | May 2007 | B2 |
7214194 | Klyukin | May 2007 | B2 |
7214195 | Mitra | May 2007 | B2 |
7214202 | Vogel et al. | May 2007 | B1 |
7216263 | Takaoka et al. | May 2007 | B2 |
7217735 | Au et al. | May 2007 | B1 |
7218966 | Haefner | May 2007 | B2 |
7224281 | Santoso et al. | May 2007 | B2 |
7225005 | Kaufman et al. | May 2007 | B2 |
7225013 | Geva et al. | May 2007 | B2 |
7226415 | Haddad et al. | Jun 2007 | B2 |
7226419 | Lane et al. | Jun 2007 | B2 |
7226422 | Hatlestsad et al. | Jun 2007 | B2 |
7226426 | Thomson | Jun 2007 | B2 |
7228315 | Finitzo et al. | Jun 2007 | B2 |
7231258 | Moore et al. | Jun 2007 | B2 |
7232158 | Wilkendorf | Jun 2007 | B2 |
7232415 | Steinberg | Jun 2007 | B2 |
7233781 | Hunter et al. | Jun 2007 | B2 |
7234359 | Hirose et al. | Jun 2007 | B2 |
7236815 | Richards-Kortum et al. | Jun 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7238158 | Abend | Jul 2007 | B2 |
7241273 | Maguire et al. | Jul 2007 | B2 |
7242807 | Waupotitsch et al. | Jul 2007 | B2 |
7244122 | Jung et al. | Jul 2007 | B2 |
7248733 | Ohta | Jul 2007 | B2 |
7248916 | Bardy | Jul 2007 | B2 |
7248917 | den Boer | Jul 2007 | B2 |
7248921 | Palreddy et al. | Jul 2007 | B2 |
7250855 | Suenbuel et al. | Jul 2007 | B2 |
7252637 | Ebner et al. | Aug 2007 | B2 |
7252640 | Ni et al. | Aug 2007 | B2 |
7254425 | Lowery et al. | Aug 2007 | B2 |
7254430 | Cho et al. | Aug 2007 | B2 |
7254432 | Fine | Aug 2007 | B2 |
7257531 | Holub | Aug 2007 | B2 |
7258666 | Brown | Aug 2007 | B2 |
7258670 | Bardy | Aug 2007 | B2 |
7260064 | Basu et al. | Aug 2007 | B2 |
7260440 | Selim et al. | Aug 2007 | B2 |
7261690 | Teller et al. | Aug 2007 | B2 |
7261735 | Lianos et al. | Aug 2007 | B2 |
7263073 | Petite et al. | Aug 2007 | B2 |
7263688 | Pitzel et al. | Aug 2007 | B2 |
7264591 | Brown | Sep 2007 | B2 |
7265676 | Gordon et al. | Sep 2007 | B2 |
7269476 | Ratnakar | Sep 2007 | B2 |
7269483 | Schubert et al. | Sep 2007 | B2 |
7269484 | Hein | Sep 2007 | B2 |
7269718 | Alexander, III et al. | Sep 2007 | B2 |
7270374 | Moriggi | Sep 2007 | B2 |
7272435 | Rowlandson | Sep 2007 | B2 |
7273053 | Zocca et al. | Sep 2007 | B2 |
7275829 | Sugiura et al. | Oct 2007 | B2 |
7275867 | Lee | Oct 2007 | B2 |
7276031 | Norman et al. | Oct 2007 | B2 |
7277744 | Schaefer et al. | Oct 2007 | B2 |
7277747 | Cazares et al. | Oct 2007 | B2 |
7277903 | Petrocelli | Oct 2007 | B2 |
7278179 | Schneider | Oct 2007 | B2 |
7280858 | Al-Ali et al. | Oct 2007 | B2 |
7280992 | Nitz | Oct 2007 | B2 |
7283153 | Provost et al. | Oct 2007 | B2 |
7284061 | Matsubayashi et al. | Oct 2007 | B2 |
7285090 | Stivoric et al. | Oct 2007 | B2 |
7286648 | Chang et al. | Oct 2007 | B1 |
7286872 | Kramer et al. | Oct 2007 | B2 |
7286877 | Daum | Oct 2007 | B2 |
7289029 | Medema et al. | Oct 2007 | B2 |
7289253 | Thomas | Oct 2007 | B2 |
7289883 | Wang et al. | Oct 2007 | B2 |
7289927 | Bedard et al. | Oct 2007 | B2 |
7291111 | Shertukde et al. | Nov 2007 | B2 |
7291497 | Holmes et al. | Nov 2007 | B2 |
7292719 | Arnon | Nov 2007 | B2 |
7294108 | Bornzin et al. | Nov 2007 | B1 |
7296042 | Edwards et al. | Nov 2007 | B2 |
7296238 | Zurawski | Nov 2007 | B1 |
7297108 | Iliff | Nov 2007 | B2 |
7297154 | Tu et al. | Nov 2007 | B2 |
7297280 | Krivitski et al. | Nov 2007 | B2 |
7297475 | Koiwai et al. | Nov 2007 | B2 |
7299085 | Bergelson et al. | Nov 2007 | B2 |
7299157 | Malik | Nov 2007 | B2 |
7300453 | Yon | Nov 2007 | B2 |
7300662 | Falotico et al. | Nov 2007 | B2 |
7300754 | Abi Fadel et al. | Nov 2007 | B2 |
7301256 | Marzahn | Nov 2007 | B2 |
7303555 | Makin et al. | Dec 2007 | B2 |
7303575 | Ogle | Dec 2007 | B2 |
7304580 | Sullivan et al. | Dec 2007 | B2 |
7305262 | Brodnick et al. | Dec 2007 | B2 |
7306565 | Fraden et al. | Dec 2007 | B2 |
7306953 | Probert et al. | Dec 2007 | B2 |
7308246 | Yamazaki et al. | Dec 2007 | B2 |
7308292 | Colvin et al. | Dec 2007 | B2 |
7308309 | Koh | Dec 2007 | B1 |
7308492 | Konopka et al. | Dec 2007 | B2 |
7310564 | Leyerer et al. | Dec 2007 | B2 |
7310607 | Brandt et al. | Dec 2007 | B2 |
7310615 | Lewis | Dec 2007 | B2 |
7311665 | Hawthorne et al. | Dec 2007 | B2 |
7311727 | Mazumder et al. | Dec 2007 | B2 |
7312619 | Altmann et al. | Dec 2007 | B2 |
7313529 | Thompson | Dec 2007 | B2 |
7314446 | Byrd et al. | Jan 2008 | B2 |
7314478 | Hui | Jan 2008 | B2 |
7315825 | Rosenfeld et al. | Jan 2008 | B2 |
7317821 | Chen et al. | Jan 2008 | B2 |
7318004 | Butterfield | Jan 2008 | B2 |
7318804 | Weitzel et al. | Jan 2008 | B2 |
7319386 | Collins, Jr. et al. | Jan 2008 | B2 |
7319400 | Smith et al. | Jan 2008 | B2 |
7319899 | Keizer | Jan 2008 | B2 |
7320030 | Brown | Jan 2008 | B2 |
7321862 | Rosenfeld et al. | Jan 2008 | B2 |
7324661 | Kemp et al. | Jan 2008 | B2 |
7325054 | Ishimoto | Jan 2008 | B2 |
7325297 | Xia | Feb 2008 | B2 |
7327637 | Chambers et al. | Feb 2008 | B2 |
7327861 | Choshi et al. | Feb 2008 | B2 |
7328472 | Chaffee | Feb 2008 | B2 |
7329236 | Kesten et al. | Feb 2008 | B2 |
7329266 | Royse et al. | Feb 2008 | B2 |
7330127 | Price et al. | Feb 2008 | B2 |
7331667 | Grotehusmann et al. | Feb 2008 | B2 |
7331928 | Seki et al. | Feb 2008 | B2 |
7332743 | Yang et al. | Feb 2008 | B2 |
7333002 | Bixler et al. | Feb 2008 | B2 |
7333014 | Agrawal et al. | Feb 2008 | B2 |
7333844 | Jones et al. | Feb 2008 | B2 |
7336018 | Augesky | Feb 2008 | B2 |
7336166 | Akamatsu | Feb 2008 | B2 |
7336187 | Hubbard, Jr. et al. | Feb 2008 | B2 |
7336202 | Kawai et al. | Feb 2008 | B2 |
7336804 | Steffin | Feb 2008 | B2 |
7337677 | Mizohata | Mar 2008 | B2 |
7337680 | Kantro | Mar 2008 | B2 |
7338443 | Tucker | Mar 2008 | B1 |
7338482 | Lockwood et al. | Mar 2008 | B2 |
7339299 | Sesita et al. | Mar 2008 | B2 |
7339587 | Kropfeld | Mar 2008 | B2 |
7340077 | Gokturk et al. | Mar 2008 | B2 |
7340240 | McDonald | Mar 2008 | B2 |
7340293 | McQuilkin | Mar 2008 | B2 |
7340337 | Katrak | Mar 2008 | B2 |
7340687 | Sekiguchi et al. | Mar 2008 | B2 |
7340951 | Nyce et al. | Mar 2008 | B2 |
7343305 | Benn et al. | Mar 2008 | B2 |
7344518 | McGuckin, Jr. et al. | Mar 2008 | B2 |
7346203 | Turek et al. | Mar 2008 | B2 |
7346205 | Walker, Jr. | Mar 2008 | B2 |
7359747 | Iwanczyk et al. | Apr 2008 | B2 |
7369892 | Ferek-Petric | May 2008 | B2 |
7374540 | Schnall | May 2008 | B2 |
7389142 | Holmström | Jun 2008 | B2 |
7519210 | Hirsch et al. | Apr 2009 | B2 |
7531133 | Hole et al. | May 2009 | B2 |
7603166 | Casscells, III et al. | Oct 2009 | B2 |
7623908 | Boppart et al. | Nov 2009 | B2 |
7637879 | Barak et al. | Dec 2009 | B2 |
7654997 | Makower et al. | Feb 2010 | B2 |
7664548 | Amurthur et al. | Feb 2010 | B2 |
7666151 | Sullivan et al. | Feb 2010 | B2 |
7729747 | Stranc et al. | Jun 2010 | B2 |
7740612 | Hochman | Jun 2010 | B2 |
7780623 | Soltanpour | Aug 2010 | B2 |
7785258 | Braig et al. | Aug 2010 | B2 |
7789830 | Ishida et al. | Sep 2010 | B2 |
7828739 | Arnold | Nov 2010 | B2 |
7833239 | Nash | Nov 2010 | B2 |
7894874 | Lynch et al. | Feb 2011 | B2 |
7931600 | Hatlestad et al. | Apr 2011 | B2 |
7938796 | Moubayed et al. | May 2011 | B2 |
8005686 | Smith | Aug 2011 | B2 |
8096946 | Burton | Jan 2012 | B2 |
8157442 | Van de Velde et al. | Apr 2012 | B2 |
8206331 | Gura et al. | Jun 2012 | B2 |
8597194 | Barak | Dec 2013 | B2 |
8920402 | Nash et al. | Dec 2014 | B2 |
20010000262 | McEwen et al. | Apr 2001 | A1 |
20010031920 | Kaufman et al. | Oct 2001 | A1 |
20010031981 | Evans et al. | Oct 2001 | A1 |
20010044588 | Mault | Nov 2001 | A1 |
20010047137 | Moreno et al. | Nov 2001 | A1 |
20020016535 | Martin et al. | Feb 2002 | A1 |
20020042583 | Barak et al. | Apr 2002 | A1 |
20020091319 | Moehring et al. | Jul 2002 | A1 |
20020099286 | Sandler et al. | Jul 2002 | A1 |
20020107504 | Gordon | Aug 2002 | A1 |
20020111601 | Thompson | Aug 2002 | A1 |
20020128545 | Steuer et al. | Sep 2002 | A1 |
20020151795 | Palti | Oct 2002 | A1 |
20020198459 | Franco et al. | Dec 2002 | A1 |
20030026798 | Zimmerman et al. | Feb 2003 | A1 |
20030050542 | Reihl et al. | Mar 2003 | A1 |
20030065285 | Higuchi | Apr 2003 | A1 |
20030065536 | Hansen et al. | Apr 2003 | A1 |
20030069481 | Hervy et al. | Apr 2003 | A1 |
20030083698 | Whitehurst et al. | May 2003 | A1 |
20030092975 | Casscells, III et al. | May 2003 | A1 |
20030139778 | Fischell et al. | Jul 2003 | A1 |
20030143158 | Wescott et al. | Jul 2003 | A1 |
20030149997 | Hageman | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030195401 | Tian et al. | Oct 2003 | A1 |
20030208116 | Liang et al. | Nov 2003 | A1 |
20030229691 | Ishimoto | Dec 2003 | A1 |
20040019278 | Abend | Jan 2004 | A1 |
20040019303 | Thomson | Jan 2004 | A1 |
20040024298 | Marshik-Geurts et al. | Feb 2004 | A1 |
20040030270 | Johnson | Feb 2004 | A1 |
20040030578 | Cross et al. | Feb 2004 | A1 |
20040034284 | Aversano et al. | Feb 2004 | A1 |
20040039264 | Bardy | Feb 2004 | A1 |
20040039268 | Barbour et al. | Feb 2004 | A1 |
20040073146 | Weintraub et al. | Apr 2004 | A1 |
20040091933 | Stoughton et al. | May 2004 | A1 |
20040111016 | Casscells, III et al. | Jun 2004 | A1 |
20040116822 | Lindsey | Jun 2004 | A1 |
20040122354 | Semba | Jun 2004 | A1 |
20040133081 | Teller et al. | Jul 2004 | A1 |
20040133082 | Abraham-Fuchs et al. | Jul 2004 | A1 |
20040138562 | Makower et al. | Jul 2004 | A1 |
20040143401 | Elling | Jul 2004 | A1 |
20040147837 | Macaulay et al. | Jul 2004 | A1 |
20040147956 | Hovanes et al. | Jul 2004 | A1 |
20040171971 | Ravikumar et al. | Sep 2004 | A1 |
20040176668 | Goldstein | Sep 2004 | A1 |
20040176700 | Potter | Sep 2004 | A1 |
20040186383 | Rava et al. | Sep 2004 | A1 |
20040208343 | Golden et al. | Oct 2004 | A1 |
20040210208 | Paul et al. | Oct 2004 | A1 |
20040212505 | Dewing et al. | Oct 2004 | A1 |
20040219608 | Der-Balian | Nov 2004 | A1 |
20040236192 | Necola Shehada et al. | Nov 2004 | A1 |
20040236225 | Murphy et al. | Nov 2004 | A1 |
20040249293 | Sandler et al. | Dec 2004 | A1 |
20040260346 | Overall et al. | Dec 2004 | A1 |
20040265393 | Unger et al. | Dec 2004 | A1 |
20050004461 | Abend | Jan 2005 | A1 |
20050027184 | Saldivar et al. | Feb 2005 | A1 |
20050033154 | deCharms | Feb 2005 | A1 |
20050034485 | Klefstad-Sillonville et al. | Feb 2005 | A1 |
20050075531 | Loeb et al. | Apr 2005 | A1 |
20050080336 | Byrd et al. | Apr 2005 | A1 |
20050085769 | MacMahon et al. | Apr 2005 | A1 |
20050090736 | Sommer | Apr 2005 | A1 |
20050090748 | Makower et al. | Apr 2005 | A1 |
20050096528 | Fritz et al. | May 2005 | A1 |
20050124864 | Mack et al. | Jun 2005 | A1 |
20050124969 | Fitzgerald et al. | Jun 2005 | A1 |
20050129731 | Horres et al. | Jun 2005 | A1 |
20050142210 | Porter | Jun 2005 | A1 |
20050148854 | Ito et al. | Jul 2005 | A1 |
20050148899 | Walker et al. | Jul 2005 | A1 |
20050148953 | Fulton, III | Jul 2005 | A1 |
20050159690 | Barak et al. | Jul 2005 | A1 |
20050165325 | Hornig | Jul 2005 | A1 |
20050175665 | Hunter et al. | Aug 2005 | A1 |
20050176678 | Horres et al. | Aug 2005 | A1 |
20050186245 | Hunter et al. | Aug 2005 | A1 |
20050222526 | Perry et al. | Oct 2005 | A1 |
20050234393 | Wood, Jr. | Oct 2005 | A1 |
20050234398 | Wood, Jr. | Oct 2005 | A1 |
20050234399 | Wood, Jr. | Oct 2005 | A1 |
20050234440 | Wood, Jr. | Oct 2005 | A1 |
20050240102 | Rachlin et al. | Oct 2005 | A1 |
20050261726 | Pile-Spellman | Nov 2005 | A1 |
20050287134 | Klein | Dec 2005 | A1 |
20050288590 | Kaplan | Dec 2005 | A1 |
20060010012 | Franzblau et al. | Jan 2006 | A1 |
20060047301 | Ogle | Mar 2006 | A1 |
20060052678 | Drinan et al. | Mar 2006 | A1 |
20060062448 | Hirsch et al. | Mar 2006 | A1 |
20060069425 | Hillis et al. | Mar 2006 | A1 |
20060074362 | Rousso et al. | Apr 2006 | A1 |
20060079784 | Shifrin | Apr 2006 | A1 |
20060089556 | Bambot et al. | Apr 2006 | A1 |
20060100530 | Kliot et al. | May 2006 | A1 |
20060124140 | Forsell | Jun 2006 | A1 |
20060127246 | Forsell | Jun 2006 | A1 |
20060135940 | Joshi | Jun 2006 | A1 |
20060142783 | Lewis et al. | Jun 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060173321 | Kubota et al. | Aug 2006 | A1 |
20060181791 | Van Beck et al. | Aug 2006 | A1 |
20060184280 | Oddsson et al. | Aug 2006 | A1 |
20060224225 | Ransbury et al. | Oct 2006 | A1 |
20060235286 | Stone et al. | Oct 2006 | A1 |
20060241521 | Cohen | Oct 2006 | A1 |
20060253301 | Simms et al. | Nov 2006 | A1 |
20060264758 | Hossack et al. | Nov 2006 | A1 |
20060290516 | Muehlsteff et al. | Dec 2006 | A1 |
20060293572 | Bulat | Dec 2006 | A1 |
20070010719 | Huster et al. | Jan 2007 | A1 |
20070010868 | Ferren et al. | Jan 2007 | A1 |
20070016079 | Freeman et al. | Jan 2007 | A1 |
20070021458 | Ishikawa et al. | Jan 2007 | A1 |
20070021774 | Hogendijk | Jan 2007 | A1 |
20070038042 | Freeman et al. | Feb 2007 | A1 |
20070043308 | Lee | Feb 2007 | A1 |
20070054266 | Sato et al. | Mar 2007 | A1 |
20070060811 | Roberts | Mar 2007 | A1 |
20070066929 | Ferren et al. | Mar 2007 | A1 |
20070078500 | Ryan et al. | Apr 2007 | A1 |
20070083090 | Sterling et al. | Apr 2007 | A1 |
20070088334 | Hillis et al. | Apr 2007 | A1 |
20070100278 | Frei et al. | May 2007 | A1 |
20070104653 | Miller et al. | May 2007 | A1 |
20070129639 | Zhang et al. | Jun 2007 | A1 |
20070142905 | Hezi-Yamit et al. | Jun 2007 | A1 |
20070156211 | Ferren et al. | Jul 2007 | A1 |
20070161921 | Rausch | Jul 2007 | A1 |
20070161933 | Ravikumar | Jul 2007 | A1 |
20070166707 | Schadt et al. | Jul 2007 | A1 |
20070167751 | Schilling et al. | Jul 2007 | A1 |
20070168024 | Khairkhahan | Jul 2007 | A1 |
20070177781 | Raffy | Aug 2007 | A1 |
20070185470 | Steinbach et al. | Aug 2007 | A1 |
20070186923 | Poutiatine et al. | Aug 2007 | A1 |
20070191740 | Shertukde et al. | Aug 2007 | A1 |
20070207131 | Boss, Jr. et al. | Sep 2007 | A1 |
20070213600 | John et al. | Sep 2007 | A1 |
20070213613 | Ishida et al. | Sep 2007 | A1 |
20070232930 | Freeman et al. | Oct 2007 | A1 |
20070232940 | Fine et al. | Oct 2007 | A1 |
20070232958 | Donofrio et al. | Oct 2007 | A1 |
20070233019 | Forsell | Oct 2007 | A1 |
20070255122 | Vol et al. | Nov 2007 | A1 |
20070255199 | Dewey | Nov 2007 | A1 |
20080004550 | Einav et al. | Jan 2008 | A1 |
20080033307 | Baudoin et al. | Feb 2008 | A1 |
20080044072 | Kiraly et al. | Feb 2008 | A1 |
20080058758 | Ranchod et al. | Mar 2008 | A1 |
20080071185 | Beck et al. | Mar 2008 | A1 |
20080077019 | Xiao et al. | Mar 2008 | A1 |
20080091138 | Pastore et al. | Apr 2008 | A1 |
20080097499 | Nash et al. | Apr 2008 | A1 |
20080103397 | Barak | May 2008 | A1 |
20080132976 | Kane et al. | Jun 2008 | A1 |
20080146970 | Litman et al. | Jun 2008 | A1 |
20080161698 | Sum et al. | Jul 2008 | A1 |
20080208011 | Shuler | Aug 2008 | A1 |
20080221457 | Zeng et al. | Sep 2008 | A1 |
20080242952 | Jung et al. | Oct 2008 | A1 |
20080262344 | Brummett | Oct 2008 | A1 |
20080275314 | Mack et al. | Nov 2008 | A1 |
20080275393 | Bonnette et al. | Nov 2008 | A1 |
20080294019 | Tran | Nov 2008 | A1 |
20080300493 | Gatto et al. | Dec 2008 | A1 |
20080320098 | Jung et al. | Dec 2008 | A1 |
20090005724 | Regittnig et al. | Jan 2009 | A1 |
20090012382 | Dutta et al. | Jan 2009 | A1 |
20090030298 | Matthews et al. | Jan 2009 | A1 |
20090048577 | Gillies et al. | Feb 2009 | A1 |
20090063518 | Jung et al. | Mar 2009 | A1 |
20090069720 | Beck et al. | Mar 2009 | A1 |
20090088614 | Taub | Apr 2009 | A1 |
20090157058 | Ferren et al. | Jun 2009 | A1 |
20090198129 | Varghese et al. | Aug 2009 | A1 |
20090227997 | Wang et al. | Sep 2009 | A1 |
20090234672 | Dicks et al. | Sep 2009 | A1 |
20090287093 | Ferren et al. | Nov 2009 | A1 |
20090287101 | Ferren et al. | Nov 2009 | A1 |
20090287191 | Ferren et al. | Nov 2009 | A1 |
20090299156 | Simpson et al. | Dec 2009 | A1 |
20090306484 | Kurtz et al. | Dec 2009 | A1 |
20090306487 | Crowe et al. | Dec 2009 | A1 |
20090324608 | Meyers et al. | Dec 2009 | A1 |
20100016733 | Smith et al. | Jan 2010 | A1 |
20100063365 | Pisani et al. | Mar 2010 | A1 |
20100069757 | Yoshikawa et al. | Mar 2010 | A1 |
20100152644 | Pesach et al. | Jun 2010 | A1 |
20100228135 | Schulhauser et al. | Sep 2010 | A1 |
20100234714 | Mercier et al. | Sep 2010 | A1 |
20100268112 | Short et al. | Oct 2010 | A1 |
20110068928 | Riley et al. | Mar 2011 | A1 |
20110087113 | Mack et al. | Apr 2011 | A1 |
20110098546 | Farazi et al. | Apr 2011 | A1 |
20110112416 | Myr | May 2011 | A1 |
20110160549 | Saroka et al. | Jun 2011 | A1 |
20110201955 | Hatlestad et al. | Aug 2011 | A1 |
20110257577 | Lane et al. | Oct 2011 | A1 |
Number | Date | Country |
---|---|---|
7059754 | Mar 1995 | JP |
WO 9414487 | Jul 1994 | WO |
WO 2005046482 | May 2005 | WO |
WO 2006109072 | Oct 2006 | WO |
WO 2007067952 | Jun 2007 | WO |
WO 2007093804 | Aug 2007 | WO |
WO 2007122375 | Nov 2007 | WO |
Entry |
---|
Butty, V.D. et al.; “Residence Times and Basins of Attraction for a Realistic Right Internal Carotid Artery With Two Aneurysms”; Biorheology; 2002; pp. 387-393; vol. 39; IOS Press. |
Caceres-Loriga, Fidel Manuel et al.; “Thrombolytic Treatment as First Option in Recurrent Tricuspid Prosthetic Valve Thrombosis and Ebstein's Anomaly”; J. Pharm. Pharmaceut Sci; 2005; pp. 332-334; located at: www.cspsCanada.org. |
Das, Moloy et al.; “Is Thrombolysis or Surgery the Best Option for Actue Prosthetic Valve Thrombosis?”; Interactive CardioVascular and Thoracic Surgery; 2007; pp. 806-812; vol. 6; located at: www.icvts.ctsnetjournals.org. |
Kasai, Chihiro et al.; “Real-Time Two-Dimensional Blood Flow Imaging Using an Autocorrelation Technique”; IEEE Transactions on Sonics Ultrasonics; May 1985; pp. 458-464; vol. SU-32, No. 3; IEEE. |
“Prioritizing Interventions to Improve Rates of Thrombolysis for Ischemic Stroke”; Neurology: California Acute Stroke Pilot Registry Investigators; 2005; pp. 654-659; vol. 64; located at: www.neurology.org. |
Roscitano, Antonino et al.; “Case Report: Acute Dysfunction from Thrombosis of a Mechanical Mitral Valve Prosthesis”; Braz J Cardiovasc Surg; 2005; pp. 88-90; vol. 20, No. 1; Dept. of Cardiac Surgery, St. Andrea Hospital, “La Sapienza” University, Rome, Italy. |
Watrous, Raymond L. et al.; “Computer-Assisted Detection of Systolic Murmurs Associated with Hypertrophic Cardiomyopathy”; Tex Heart Inst J; 2004; pp. 368-375; vol. 31, No. 4. |
CareSelections; Wound Care Therapy Products, Pulmonary Care Therapy Products, Bariatric Therapy Products; pp. 1-8; located at: www.CareSelections.com, 2005. |
Edwards, David et al.; “99mTc-NC100668, an Agent for Imaging Venous Thromboembolism: The Effect of Anticoagulant or Thrombolytic Therapy on the Upake and Retuntion of Radioactivity in Blood Clots in Vivio”; Nuclear Medicine Communications; dated 2007; pp. 55-62; vol. 28; Lippincott Williams & Wilkins. |
Gatto, Rodolfo et al.; “Optical Microprobe for Blood Clot Detection”; Biomedical Optics, Technical Digest; dated Mar. 19, 2006; pp. 1-3; located at: http://www.opticsinfobase.org/abstract.cfm?URI=BIO-2006-ME47. |
Gatto, Rodolfo et al.; “Optical Probe for Blood Clot Detection”; Journal of Applied Spectroscopy; dated 2007; pp. 1-19; located at; http://rodolfogatto.com/papers/Gatto—2007—Optical%20Probe—AS.pdf. |
Greco, Frank A.; “Reflectance Spectroscopy of Clotting Blood: A Description of the Time-Dependent Behavior”; Arch Pathol Lab Med; Dated Feb. 2004; pp. 173-180; vol. 128. |
He, Hongying et al.; “Computed Tomography Evaluation of Right Heart Dysfunction in Patients with Acute Pulmonary Embolism”; J. Comput Assist. Tomogr.; dated Mar./Apr. 2006; pp. 262-266; vol. 30, No. 2; Lippincott Williams & Wilkins. |
Hart, James et al.; “P.O. Pro Wireless Reflectance Pulse Oximeter: Design 1”; dated Nov. 10, 2004; pp. 1-30; located at: www.bme.uconn.edu/sendes/Spring05/Team3/papers/design2.doc. |
Hintz, Susan R. et al.; “Bedside Imaging of Intracranial Hemorrhage in the Neonate Using Light: Comparison with Ultrasound, Computed Tomography, and Magnetic Resonance Imagine”; Pediatric Research; dated May 1999; pp. 737-738; vol. 45; International Pediatrics Research Foundation, Inc. |
Hunter, James B. et al.; “Methods of Anaesthesia Used for Reduction of Colles' Fractures”; BMJ; dated Nov. 25, 1989; pp. 1316-1317; vol. 299, No. 6711; located at; http://ukpmc.ac.uk/articlerender.cgi?artid=932375. |
ISSYS: Integrated Sensing Systems—Press Release: ISSYS Receives Phase II SBIR Grant from NSF for Development of WaferScale, Mermetric, Hybrid Integration of MEMS and Electronics; dated Oct. 2, 2007; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSY Receives Patent for Fuel & Fluid Quality Sensor; dated Sep. 18, 2007; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSY Receives Patent for Fuel Cell Sensor; dated Aug. 21, 2007; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: NSF Awards a Phase I SBIR to ISSYS Inc. for Investigating Two-Phase Microfluidic Behavior and Nanoliter Bubble Dection; dated Jul. 17, 2007; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSYS Inc. Awarded a Patent for Wireless, Batteryless, Implantable Sensors; dated Jul. 5, 2007; p. 1. |
ISSYS: Integrated Sensing Systems—Press Release: ISSY to Present Fuel Cell Sensor Poster at the “SME Tomorrow's Energy . . . Today 2006” Conference; dated Oct. 3, 2006; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSY Will Exhibit at the Medical Design & Manufacturing Exposition and Conference; dated Sep. 26, 2006; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSYS Methanol Concentration Sensor to be Featured at the JAIMA Exposition; dated Aug. 29, 2006; pp. 1-2. |
ISSYS: Integrated Sensing Systems—Press Release: ISSYS Awarded New Patent for a Resonant Tube Viscosity Sensing Device; dated Jun. 21, 2006; pp. 1-2. |
Kim, Tae Min et al.; “Clinical Predictors of Recurrent Venous Thromboembolism: A Single Institute Experience in Korea”; Thrombosis Research; dated 2008; pp. 1-7; Elsevier Ltd. |
Morris, Timothy A. et al.; “Improved Imaging of Deep Venous Thrombi During Anticoagulation Using Radiolabelled Anti-D-Dimer Antibodies”; Nuclear Medicine Communications; dated 2004; pp. 917-922; vol. 25; Lippincott Williams & Wilkins. |
Parker, Martyn J.; “We Need Look Critically at Evidence for Universal Use”; BMJ; dated May 24, 2008; pp. 1145-1148; vol. 336; located at: http://www.bmj.com/cgi/content/short/336/7654/1148. |
Rossow, Molly J. et al.; “Blood Flow Measurements and Clot Detection with Near-Infrared Spectroscopy”; Optics InfoBase—Conference Paper: Biomedical Topical Meeting, Ft. Lauderdale, FL; dated Mar. 19, 2006; pp. 1-3; OSA/BOSD, AOIMP, TLA. |
Roumen-Klappe, E.M.; “Multilayer Compression Bandaging in the Acute Phase of Deep-Vein Thrombosis Has no. Effect on the Development of the Post-Thrombotic Syndrome”; J. Thromb Thrombolysis; dated 2008; pp. 1-5; Springer. |
So-Ling, Carmen et al.; “A Multi-Layered Reflection Model of Natural Human Skin”; CGI: Computer Graphics International; dated 2001; p. 0249; (only abstract provided). |
Stone, Michael J. et al.; “Pulsed-High Intensity Focused Ultrasound Enhanced tPA Mediated Thrombolysis in a Novel in Vivo Clot Model, A Pilot Study”; Thromb Res.; dated 2007; pp. 193-202; vol. 121, No. 2; NIH Public Access Author Manuscript. |
Vidal Melo, Marcos F. et al.; “Changes in Regional Ventilation Afer Autologus Blood Clot Pulmonary Embolism”; Anesthesiology; dated Sep. 2002; pp. 671-681; vol. 97, No. 3; American Society of Anesthesiologists, Inc. |
Walsh, Fergus; “Scanner Spots Deadly Blood Clots”; BBC News; dated Apr. 13, 2007; pp. 1-3; located at: http://news.bbc.co.uk/2/hi/health/6541279.stm. |
Wieringa F.P. et al.; “Remote Non-Invasive Stereoscopic Imaging of Blood Vessels: First In-Vivo Results of a New Multispectral Contrast Enhancement Technology”; Annals of Biomedical Engineering; dated Dec. 2006; pp. 1870-1878; vol. 34, No. 12; Biomedical Engineering Society. |
Xie, Hua et al.; “Staging Deep Venous Thrombosis Using Ultrasound Elasticity Imaging: Animal Model”; Ultrasound in Med. & Biol.; dated 2004; pp. 1385-1396; vol. 30, No. 10; World Federation for Ultrasound in Medicine & Biology. |
Zhang, Quan et al.; “Study of Near Infrared Technology for Intracranial Hematoma Detection”; Journal of Biomedical Optics; dated Apr. 2000; pp. 206-213; vol. 5, No. 2. |
Brill, S. et al.; “Bier's Block: 100 Years Old and Still Going Strong”; Acta Anaesthesiologica Scandinavica; 2004; pp. 117-122; vol. 48; Acta Anaesthesiol Scand. |
Brown, Eli M. et al.; “A Case Report: Prolongad Intravenous Regional Anestesia”; Anestesia and Analgesia Current Researches; May-Jun. 1966; pp. 319-321; vol. 45; located at: http://www.anesth-analg.org/cgi/reprint/45/3/319. |
“Exmocare: Answers to Frequently Asked Questions”; Exmocare; printed on Mar. 18, 2008; pp. 1-4; located at: http://www.exmocare.com/faq. |
“Exmocare: BT2”; Exmocare; printed on Mar. 18, 2008; pp. 1-5; located at: http://www.exmocare.com/bt2/. |
Mabee, John et al.; “Basic Investigations: Bier Block Exsanguination: A Volumetric Comparison and Venous Pressure Study”; Academic Emergency Medicine; Feb. 2000; pp. 105-113; vol. 7, No. 2; located at: http://www.ncbi.nlm.nih.gov/pubmed/10691067. |
Moradkhan, Raman et al.; “Metabolic Forearm Vasodilation is Enhanced Following Bier Block with Phentolamine”; Am J Physiol Heart Circ Physiol; Aug. 3, 2007; pp. H2289-H2295; vol. 293; located at: http://ajpheart.physiology.org/cgi/content/abstract/293/4/H2289 (only abstract provided), pp. 1-15. |
“Phase 1 of the BT2 is Now Complete”; Exmocare—Phase I of the BT2 vital signs wristwatch complete; printed on May 12, 2008; pp. 1-9; located at: http://www.exmocare.com/index.html. |
Spanner, K.; “Survey of the Various Operating Principles of Ultrasonic Piezomotors”; Actuator 2006; pp. 1-8; located at; http://www.pi-usa.us/technotes/Actuator2006—SurveyoftheVariousOperatingPrinciplesofUltrasonicPiezomotors—c.pdf. |
Taskaynatan, Mehmet Ali et al.; “Bier Block With Methylprednisolone and Lidocaine in CRPS Type I: A Randomized, Double-Blinded, Placebo-Controlled Study”; Regional Anesthesia and Pain Medicine; Sep.-Oct. 2004; pp. 408-412; vol. 29, No. 5; American Society of Regional Anesthesia and Pain Medicine. |
Dieter, Robert S. et al.; “Prosthetic Heart Valve Thrombosis: An Overview”; Wisconsin Medical Journal; Bearing a date of 2002; pp. 67-68; vol. 101, No. 7. |
Landry, Anthony et al.; “Theoretical and experimental quantification of carotid plaque volume measurements made by three-dimensional ultrasound using test phantoms”; Medical Physics; bearing a date of Oct. 2002; pp. 2319-2327; vol. 29, No. 10; American Association Physical Medicine. |
Mackinnon, Andrew D. et al.; “Long-Term Ambulatory Monitoring for Cerebral Emboli Using Transcranial Doppler Ultrasound”; STROKE; Journal of the American Heart Association; originally published Dec. 18, 2003; pp. 73-78; American Heart Association. |
Weil, M. H.; “Defining Hemodynamic Instability”; Update in Intensive Care and Emergency Medicine; 2005 ; pp. 9-17, (2 page abstract printed on Aug. 16, 2011) ; vol. 42, part 2; (abstract located at: http://www.springerlink.com/content/1h3g72p32621125j/). |
Baumgartner et al.; “Factors Controlling Thrombus Formation on Arterial Lesions”; Annals New York Academy of Sciences; Oct. 1985; pp. 162-177; vol. 454; Issue 1. |
Smith et al.; “A Comparison of Four Methods for Distinguishing Doppler Signals From Gaseous and Particulate Emboli”; Journal of the American Heart Association; Jun. 1998; pp. 1133-1138; vol. 29; No. 6; American Heart Association; Dallas, TX. |
Carter, J. Stein; “Circulatory System”; bearing a date of Nov. 13, 2006; pp. 1-5; http://biology.cic.uc.edu/courses/bio105/circulat.htm. |
Thefreedictionary.com; “Tonometer”; bearing a date of 2012, printed on Jun. 13, 2012; pp. 1-4; Farlex, Inc.; http://medical-dictionary.thefreedictionary.com/tonometer. |
Lamuraglia et al.; “Optical Properties of Human Arterial Thrombus Vascular Grafts, and Sutures: Implications for Selective Laser Thrombus Ablation”; Dec. 1990; pp. 2200-2206; vol. 26, No. 12; IEEE Journal of Quantum Electronics. |
Spencer et al.; “Upper Extremity Deep Vein Thrombosis: A Community-Based Perspective: The Worcester Venous Thromboembolism Study”; Aug. 2007; pp. 678-684; vol. 120, No. 8; American Journal of Medicine. |
Stedman's Medical Dictionary 28th Edition; bearing a date of 2006; p. 1329; ISBN 0-7817-3390-1; Lippincott Williams & Wilkins. |
Number | Date | Country | |
---|---|---|---|
20090157054 A1 | Jun 2009 | US |